Northwest Biotherapeutics, Inc. (NWBO)
OTCMKTS · Delayed Price · Currency is USD
0.1265
-0.0125 (-8.99%)
At close: Nov 20, 2026
Northwest Biotherapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Operating Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -39.66 | -60.16 | -83.78 | -62.6 | -105.03 | 179.13 |
Depreciation & Amortization | 3.39 | 2.34 | 2.04 | 1.73 | 1.5 | 0.59 |
Other Amortization | 1.59 | 1.89 | 2.48 | 2.37 | 2.77 | 2.3 |
Stock-Based Compensation | 0.8 | 1.21 | 3.46 | 4.41 | 12.3 | 15.5 |
Other Operating Activities | -14.14 | -3 | 8.78 | 4.14 | 28.48 | -238.54 |
Change in Accounts Payable | 4.82 | 13.69 | 9.85 | -4.43 | 6.85 | -0.6 |
Change in Other Net Operating Assets | -0.33 | -0.73 | 0.16 | 0.73 | 0.36 | 3.32 |
Operating Cash Flow | -43.2 | -44.76 | -57.02 | -53.64 | -52.78 | -38.3 |
Operating Cash Flow Growth | - | - | - | - | - | - |
Investing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Capital Expenditures | -1.29 | -1.5 | -1.01 | -3.44 | -2.9 | -6.02 |
Investing Cash Flow | -1.29 | -1.82 | -1.01 | -3.44 | -2.9 | -6.02 |
Financing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Short-Term Debt Issued | - | - | 0.2 | 0.01 | 2.57 | 0.25 |
Long-Term Debt Issued | - | 31.26 | 34.02 | 33.34 | 5.6 | 29.67 |
Total Debt Issued | 36.15 | 31.26 | 34.22 | 33.35 | 8.17 | 29.92 |
Long-Term Debt Repaid | - | -1.27 | -1.43 | -0.39 | -5.49 | -5.83 |
Total Debt Repaid | -2.4 | -1.27 | -1.43 | -0.39 | -5.49 | -5.83 |
Net Debt Issued (Repaid) | 33.75 | 29.99 | 32.78 | 32.96 | 2.68 | 24.09 |
Issuance of Common Stock | 5.05 | 19.34 | 15.75 | 1.72 | 20.57 | 24.05 |
Other Financing Activities | 0 | - | 0.05 | 4.75 | - | - |
Financing Cash Flow | 38.8 | 49.33 | 56.79 | 52.76 | 41.97 | 48.13 |
Net Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Foreign Exchange Rate Adjustments | 1.85 | -1.88 | 1.3 | -0.52 | 5.51 | 1.37 |
Net Cash Flow | -3.84 | 0.87 | 0.05 | -4.84 | -8.2 | 5.19 |
Free Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -44.49 | -46.27 | -58.03 | -57.07 | -55.68 | -44.31 |
Free Cash Flow Growth | - | - | - | - | - | - |
Free Cash Flow Margin | -1557.60% | -3357.55% | -4199.06% | -2954.14% | -3308.20% | -4409.35% |
Free Cash Flow Per Share | -0.03 | -0.03 | -0.05 | -0.05 | -0.06 | -0.04 |
Levered Free Cash Flow | -37.94 | -23.95 | -30.19 | -118.13 | -44.98 | -270 |
Unlevered Free Cash Flow | -33.65 | -20.4 | -27.81 | -117.23 | -43.96 | -269.17 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash Interest Paid | 0.39 | 0.39 | 0.13 | 0.06 | 0.91 | 1.73 |
Change in Working Capital | 4.49 | 12.96 | 10 | -3.7 | 7.21 | 2.73 |